Secondary Mitochondrial Dysfunction as a Cause of Neurodegenerative Dysfunction in Lysosomal Storage Diseases and an Overview of Potential Therapies

Int J Mol Sci. 2022 Sep 12;23(18):10573. doi: 10.3390/ijms231810573.


Mitochondrial dysfunction has been recognised a major contributory factor to the pathophysiology of a number of lysosomal storage disorders (LSDs). The cause of mitochondrial dysfunction in LSDs is as yet uncertain, but appears to be triggered by a number of different factors, although oxidative stress and impaired mitophagy appear to be common inhibitory mechanisms shared amongst this group of disorders, including Gaucher's disease, Niemann-Pick disease, type C, and mucopolysaccharidosis. Many LSDs resulting from defects in lysosomal hydrolase activity show neurodegeneration, which remains challenging to treat. Currently available curative therapies are not sufficient to meet patients' needs. In view of the documented evidence of mitochondrial dysfunction in the neurodegeneration of LSDs, along with the reciprocal interaction between the mitochondrion and the lysosome, novel therapeutic strategies that target the impairment in both of these organelles could be considered in the clinical management of the long-term neurodegenerative complications of these diseases. The purpose of this review is to outline the putative mechanisms that may be responsible for the reported mitochondrial dysfunction in LSDs and to discuss the new potential therapeutic developments.

Keywords: Gaucher disease; Niemann–Pick disease; lysosomal storage diseases; mucopolysaccharidosis; neurodegeneration; secondary mitochondrial dysfunction; type C.

Publication types

  • Review

MeSH terms

  • Gaucher Disease* / metabolism
  • Humans
  • Hydrolases / metabolism
  • Lysosomal Storage Diseases* / metabolism
  • Lysosomes / metabolism
  • Mitochondria
  • Niemann-Pick Diseases* / metabolism


  • Hydrolases

Grants and funding

This research received no external funding.